V
Verve Therapeutics
Boston, United States
Founded 2018 NASDAQ: VERV
About
Gene editing company using lipid nanoparticle delivery for cardiovascular disease treatment
Company Details
- Type
- commercial
- Employees
- 200-500
- Funding
- $500M+
Key Products
- VERVE-101
- Base Editing Platform